

CSD/BSE&NSE/BM/2022-23
August 8, 2022

To
The Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

Scrip Code: 543064

Scrip Symbol: SUVENPHAR

Dear Sir/Madam,

Sub: Outcome of the Board Meeting

.....

With reference to the above subject, pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors of the company, at its meeting held today i.e. August 08, 2022, has taken on record and approved the Un-Audited Standalone and Consolidated Financial Results prepared under Ind AS along with Limited Review Reports of the Statutory Auditors for the quarter ended 30th June, 2022.

We are enclosing herewith the following documents:

- 1) Un-audited Standalone and Consolidated Financial Results for the quarter ended 30th June, 2022
- 2) Limited Review Reports on the financial results as mentioned above and
- 3) A copy of the News Release of our company

We request you to take these documents on your records. The Board Meeting commenced at 11:30 A.M. and concluded at 12:45 P.M.

This is for your information and record.

Thanking you,
Yours faithfully,
For **Suven Pharmaceuticals Limited**



K Hanumantha Rao
Company Secretary

Encl: as above

Suven Pharmaceuticals Limited

PART - I		STANDALONE			
Sl. No.	PARTICULARS	For the Quarter Ended			For the Year Ended
		30/06/2022	31/03/2022	30/06/2021	31/03/2022
		UN-AUDITED	UN-AUDITED	UN-AUDITED	AUDITED
		(1)	(2)	(3)	(4)
1	Income				
	Revenue from operations	33,879.91	36,384.72	26,380.13	132,022.21
	Other Income	1,089.75	13,439.58	578.29	18,778.80
	Total income	34,969.66	49,824.30	26,958.42	150,801.01
2	Expenses				
	a) Cost of materials consumed	11,229.40	13,027.81	9,183.96	45,945.64
	b) Purchases of stock-in-trade	-	-	-	-
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(1,564.13)	(1,994.03)	(1,508.91)	(6,035.21)
	d) Employee benefits expense	2,479.26	3,112.20	2,115.89	10,048.39
	e) R & D expense	223.23	214.42	235.24	1,035.45
	f) Finance costs	143.25	218.87	212.55	623.10
	g) Depreciation and amortisation expenses	1,054.78	1,042.08	899.33	3,909.71
	h) Manufacturing Expenses	4,138.69	4,434.34	3,884.83	17,318.86
	i) Other Expenses	1,899.49	1,833.11	1,007.47	5,710.25
	Total expenses	19,603.97	21,888.80	16,030.36	78,556.19
3	Profit before exceptional items & Tax (1-2)	15,365.69	27,935.50	10,928.06	72,244.82
4	Exceptional Items	-	-	-	-
5	Profit before Tax (3-4)	15,365.69	27,935.50	10,928.06	72,244.82
6	Tax Expenses				
	a) Current tax	3,888.10	5,148.01	2,716.35	15,763.03
	b) Deferred tax	72.42	341.02	67.59	671.91
7	Net Profit/ (Loss) for the period/year(5-6)	11,405.17	22,446.47	8,144.12	55,809.88
8	Other Comprehensive Income				
8.a	(i) Items that will not be reclassified to profit or loss	(25.48)	(18.06)	(27.96)	(101.95)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	6.41	4.55	7.03	25.66
8.b	(i) Items that will be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
	Total other Comprehensive Income	(19.07)	(13.51)	(20.93)	(76.29)
9	Total Comprehensive Income for the period (7+8)	11,386.10	22,432.96	8,123.19	55,733.59
10	Paid-up equity share capital	2,545.65	2,545.65	2,545.65	2,545.65
	Face Value of the Share	Re.1.00	Re.1.00	Re.1.00	Re.1.00
11	Other Equity	-	-	-	149,523.67
12	Earning Per Share (EPS)-Face value of Rs. 1/- each)				
	a) Basic	4.48	8.82	3.20	21.92
	b) Diluted	4.48	8.82	3.20	21.92
		(not annualised)	(not annualised)	(not annualised)	



NEWS RELEASE

HYDERABAD, INDIA (8 Aug' 2022) -- SUVEN Pharmaceuticals Limited ("SPL", "Company") today announced unaudited financial results for the quarter ended 30 June' 2022. The unaudited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 8 Aug' 2022 at Hyderabad.

Financial Snapshot

INR (Millions, except ratios and EPS)

	Quarter ended			Year ended
	30-Jun-22	31-Mar-22	30-Jun-21	31-Mar-22
Revenue from operations	3,387.99	3,638.47	2,638.01	13,202.22
Other Income	108.98	1,343.96	57.83	1,877.88
Total Income	3,496.97	4,982.43	2,695.84	15,080.10
EBITDA	1,656.37	2,919.65	1,203.99	7,677.76
EBITDA Margin	47.37%	58.60%	44.66%	50.91%
EBIT	1,550.89	2,815.44	1,114.06	7,286.79
EBIT Margin	44.35%	56.51%	41.33%	48.32%
Finance costs	14.33	21.89	21.26	62.31
Depreciation	105.48	104.21	89.93	390.97
Taxes	396.05	548.90	278.39	1,643.49
Taxes to PBT	25.78%	19.65%	25.48%	22.75%
PAT (Standalone)	1,140.52	2,244.65	814.41	5,580.99
PAT Margin (Standalone)	32.61%	45.05%	30.21%	37.01%
Associate Company	-	-	236.49	411.12
PAT (Consolidated)	1,075.42	916.68	1,050.83	4,538.05
PAT Margin (Consolidated)	30.75%	18.40%	38.98%	30.09%
EPS (Standalore)	4.48	8.82	3.20	21.92
EPS (Consolidated)	4.22	3.60	4.13	17.83
Paid up share capital (Re.1/sh)	254.56	254.56	254.56	254.56

Operational Profitability	Quarter ending			Year ending
	30-Jun-22	31-Mar-22	30-Jun-21	31-Mar-22
CDMO Revenue	3,387.99	3,638.47	2,638.01	13,202.22
Dividend from WOS	-	1,175.25	-	1,508.19
Withholding tax	-	118.45	-	167.62
Net Dividend included in PAT	-	1,056.80	-	1,340.57
Adjusted PAT	1,140.52	1,187.85	814.41	4,240.42
CDMO PAT/Income	33.66%	32.65%	30.87%	32.12%
Adjusted EBIDTA	1,656.37	1,862.85	1,203.99	6,337.19
CDMO EBIDTA/Income	48.89%	51.20%	45.64%	48.00%
Adjusted EBIT	1,550.89	1,640.19	1,114.06	5,778.60
CDMO EBIT/Income	45.78%	45.08%	42.23%	43.77%

- The Company is focused on the business of Contract Development and Manufacturing Operations (CDMO).
- The Suven Pharma Inc., the WOS of our Company has divested its entire stake (25% amounting to \$35.00 Mn) in Rising Pharma Holdings, Inc., USA on 13 Dec 2021 and accordingly, Rising Pharma Holdings, Inc., USA has ceased to be an associate company. As part of the structured deal our WOS, Suven Pharma, Inc., received in the form of cash component of \$ 41.555 Mn and a 7% stake valued at \$15.803 Mn in Raisin Aggregators L.P effective 13 Dec 2021. Hence, the share of profits of associate has not been considered in the consolidated financial statements for the Quarter ended 30 June 2022.

Suven Pharmaceuticals Limited

3. Post approval of the Board in the meeting held on 5 April 2022, the company has completed acquisition of 100% stake in Casper Pharma Private Limited (Casper Pharma) situated at GMR Hyderabad SEZ, a company engaged in formulations business for USD 20.50 Mn and has become a wholly owned subsidiary of the Company effective 22 April 2022.
4. The US Food and Drug Administration (USFDA) completed pre-approval inspection at Casper Pharma formulations manufacturing facility. The inspection was conducted from 25 through 29, July 2022. The audit was part of the agency's inspection for three product applications filed and slated to be manufactured at this site. The audit completed successfully with Zero observations and at the end of the inspection no form 483 was issued by USFDA.

For more information, please visit: <http://www.suvenpharm.com>

Risk Statement:

Except for historical information, all the statements, expectations, and assumptions, including expectations and assumptions, contained in this presentation may be forward-looking statements that involve number of risks and uncertainties. Although Suven Pharmaceuticals attempts to be accurate in making these statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause these statements to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances, and continued success in growth of sales that may make our products/services offerings less competitive; Suven Pharmaceuticals may not undertake to update any forward-looking statements that may be made from time to time.

Suven Pharmaceuticals Limited